Bayer’s drug shows a benefit in less severe chronic kidney disease patients in Figaro-DKD.
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
The group hopes phase 2 data will back approval for its amyotrophic lateral sclerosis project AMX0035 after all.
But mixed data and a previous failure provide reasons to be cautious.
Private device makers enjoy the biggest quarter for four years – and the average deal is larger than ever.
But this week three transactions did squeak through.
But with Derm Assist available free, how will the company make money?
Two new immuno-oncology mechanisms post encouraging data, giving a boost to small developers including Innate and Corvus.